Drug makers, BMGF pledge to strive for global access to COVID-19 diagnostics, therapeutics and vaccines
They assured that they will work towards developing innovations, ensuring timely availability and affordability of tools and interventions to fight the COVID-19 pandemic, their effective and equitable distribution, as well as safety
Several global life sciences companies and the Bill & Melinda Gates Foundation have pledged and committed to expand global access for COVID-19 diagnostics, therapeutics, and vaccines.
In a collective statement, they informed, “COVID-19’s existence anywhere poses a threat to communities everywhere. The health, social, and economic impacts can only be addressed through the collective actions of stakeholders across private, public, and philanthropic sectors in partnership with civil society. As organisations dedicated to improving and protecting global health, with our varied skills, roles, and resources, we remain committed to doing our part in ending this pandemic worldwide.”
The statement said, “Earlier this year AstraZeneca; Bayer; bioMérieux; Boehringer Ingelheim; Bristol Myers Squibb; Eisai; Eli Lilly; Gilead; GSK; Johnson & Johnson; Merck & Co (known as MSD outside the US and Canada); Merck KGaA, Darmstadt, Germany; Novartis; Pfizer; Roche; and Sanofi together with the Bill & Melinda Gates Foundation each pledged ourselves to the fight against COVID-19.”
The companies and BMGF said that through partnerships with other stakeholders they will strive to ensure global access to diagnostics, therapeutics, and vaccines that will help to accelerate the end of the pandemic. To accomplish this critical goal, they promised to:
Develop innovations for patients worldwide. “We will continue advancing the research and development of COVID-19 diagnostics, therapeutics, and vaccines that are suitable to meet the needs of populations around the world. To do so, we will work to expand clinical trials to account for diverse representation including lower-income settings and endeavour to address the specific product characteristics needed for use in lower-income settings even after new innovations are brought forward,” assured the companies through a statement.
Strive for timely availability. “By scaling up manufacturing at unprecedented speed and much earlier than usual, we will bring large quantities of safe and effective innovations to countries around the world for broad distribution as early as possible, no matter their income level. Mechanisms for rapidly escalating supply must be aligned with the specific context of a rapid pandemic response and tailored to each product, with options including early voluntary licensing and appropriate approaches to peer-to-peer innovator company manufacturing agreements,” they pledged.
Enable affordability for lower income countries. The companies said, “We will pursue a range of approaches to make products we are developing or supporting affordable in lower-income countries. These approaches will be independently determined by each supplier in response to the pandemic to address the significant affordability challenges, including approaches such as donations, not-for-profit supply, or equity-based tiered pricing based on countries’ needs and capabilities.”
Support effective and equitable distribution of these innovations globally. “We will strive towards equitable allocation of our products and support global mechanisms like COVAX, recognising the most effective approach to equitable access will vary across vaccines, therapeutics, and diagnostics. We also will use our collective voice alongside other global health stakeholders to advocate for the strengthening of health systems and distribution networks so crucial innovations reach everyone who needs them. In doing so, we support evidence-based prioritisation so that health care workers, high-risk individuals, and other priority groups identified by WHO and other health authorities are protected for the duration of the pandemic, regardless of the country they live in. We will advocate for equitable distribution, recognizing that sovereign nations have final decision-making authority,” they stated.
Maintain public confidence in our innovations. “We will continue making the safety of individuals who receive products we are developing or supporting the highest priority. Adherence to the strictest scientific and ethical standards in product development and in manufacturing processes will remain the top priority over speed or politics,” guaranteed the drug makers.
The collaboration has also called upon governments, multilateral institutions, companies, NGOs, and others to
- Provide sufficient, dedicated, sustainable, and timely funding for the procurement and delivery of the tools necessary to end the COVID-19 pandemic.
- Diversify representation in critical decision-making and coordination bodies with special emphasis on voices representing low-income and lower-middle-income countries.
- Continue quickly developing and communicating clear guidance on product needs in lower resource settings as early as possible as our understanding of COVID-19 and the tools to combat it evolve.
- Advance fit-for-purpose regulatory and liability processes for all stakeholders involved, which prioritize safety while not slowing down access to critical new tools.
- Build and maintain public confidence in the approval mechanisms for diagnostics, therapeutics, and vaccines by ensuring robust safety and efficacy reviews and removing unwarranted political considerations from these discussions and the approval process.
- Enhance country readiness and in-country delivery systems by ensuring adequate expertise and resources are in place for effective country planning, distribution, and follow-up for new diagnostics, therapeutics, and vaccines